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Many patients with lymphoma relapse after autologous stem cell transplantation (AutoSCT). These patients
are often considered for allogeneic stem cell transplantation (AlloSCT) if remission can be achieved. If a
tandem approach was organized, some cases of relapse might be prevented. We conducted a phase II trial of
tandem AutoSCT followed by reduced-intensity conditioning (RIC) AlloSCT for patients with high-risk lym-
phoma. High-dose chemotherapy was given with busulfan, cyclophosphamide, and etoposide. AlloSCT was
composed of RIC with busulfan/ﬂudarabine and tacrolimus, sirolimus, and methotrexate as graft-versus-host
disease (GVHD) prophylaxis. Donors were fully matched related or unrelated donors. AlloSCT was performed
any time between 40 days and 6 months after AutoSCT. Forty-two patients were enrolled, and all patients
underwent AutoSCT. RIC AlloSCT was performed in 29 patients. In the 29 patients who underwent tandem
transplant, median time from AutoSCT to AlloSCT was 96 days (range, 48 to 169). The 6-month cumulative
incidence of grades II to IV acute GVHD was 13.8% (90% conﬁdence interval [CI], 5.3% to 26.3%). Cumulative
incidence of chronic GVHD at 1 year was 37.9% (90% CI, 23.1% to 52.7%). Nonrelapse mortality at 2 years after
AlloSCT was 11.1% (90% CI, 3.5% to 23.6%). At a median follow-up of 30 months (range, 17.1 to 51.5) for the
entire group, the 2-year progression-free survival rate was 64% (90% CI, 50% to 75%) and the 2-year overall
survival rate was 69% (90% CI, 43% to 85%). For the 29 patients who underwent tandem SCT, the 2-year
progression-free survival rate was 72% (90% CI, 55% to 83%) and the 2-year OS rate was 89% (90% CI, 74% to
96%). Tandem AutoSCTeRIC AlloSCT appears to be safe and effective in patients with high-risk lymphoma.
Prospective trials using such an approach in speciﬁc lymphoma subtypes are warranted.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy with autologous hematopoietic
stem cell transplantation (AutoSCT) is a standard component
of care for many patients with relapsed/refractory Hodgkin
lymphoma (HL) and non-Hodgkin lymphoma (NHL).
Althoughmany patients can achieve durable remissions withdgments on page 1587.
equests: Yi-Bin Chen, MD, Yawkey 9E-
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ty for Blood and Marrow Transplantation.AutoSCT, disease relapse remains the principle cause of fail-
ure. Many well-deﬁned risk factors are predictive of relapse
after AutoSCT, including histology (eg, mantle cell lymphoma
[1,2] or peripheral T cell lymphoma [3]), primary refractory
disease [4], and early relapse [5].
Allogeneic hematopoietic SCT (AlloSCT) is considered in a
subgroup of patients with a chemosensitive relapse after
AutoSCT with the goal of achieving a durable remission
through an immunologically driven graft-versus-lymphoma
effect [6-9]. Increasingly, reduced-intensity conditioning
(RIC) approaches have been used for such patients given the
Table 1
Clinical and Transplant Characteristics of all Patients (n ¼ 42) and Patients
Undergoing Tandem Transplant (n ¼ 29)
All Patients
(n ¼ 42)
Patients
Undergoing
Tandem
(n ¼ 29)
Gender (male/female) 26/16 16/13
Median age (range) in years 56.5 (22-69) 56 (22-68)
Diagnosis
Rel/Ref DLBCL 10 5
Rel/Ref indolent NHL 6 5
Double-Expressing NHL 9 7
Transformed B-cell NHL 8 6
T-cell NHL 4 2
Mantle cell NHL 3 2
Rel/Ref Hodgkin 1 1
Heavy chain disease 1 1
Prior lines of chemotherapy,
median (range)
2 (1-6) 3 (1-6)
Disease status prior to ASCT
PR 21 15
CR 21 14
High-dose chemotherapy for ASCT BuCyE BuCyE
Reason for not doing AlloSCT
Disease progression 6
Patient choice 4
No suitable donor 2
Therapy-related AML 1
Median days interval between
ASCT e RIC AlloSCT (range)
96 d (48-169)
Disease status prior to AlloSCT
PR 6
CR 23
RIC for AlloSCT Bu/Flu
GVHD prophylaxis Tac/Siro/MTX
Donor type
Matched related donor 16
Matched unrelated donor 13
Median follow-up, months (range) 30.0 (17.1-51.5) 29.5 (17.1-48.0)
Rel/Ref indicates relapsed/refractory; ASCT, autologous stem cell transplant;
BEAM, BCNU, etoposide, cytarabine, melphalan; AML, acute myeloid leu-
kemia; RIC, reduced intensity conditioning; Bu/Flu, busulfan/ﬂudarabine;
Tac, tacrolimus; Siro, sirolimus; MTX, methotrexate.
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myeloablative regimens in patients with lymphoma, partic-
ularly in patients who have undergone a prior AutoSCT. Yet
for patients with aggressive lymphoma, the use of RIC regi-
mens might result in early disease relapse before the emer-
gence of an effective graft-versus-lymphoma effect [10,11].
Tandem AutoSCTeRIC AlloSCT could combine the cytotox-
icity of AutoSCT with an allogeneic graft-versus-lymphoma
effect while decreasing the morbidity and mortality associ-
ated with conventional myeloablative AlloSCT. We thus
conducted a phase II tandem AutoSCTeRIC AlloSCT trial for
patients with high-risk lymphoma.
METHODS
This study was approved by the Institutional Review Board at the Dana-
Farber Harvard Cancer Center and conducted at Dana-Farber Brigham &
Women’s Cancer Center and Massachusetts General Hospital Cancer Center.
Informed consent was obtained from all patients. This trial was registered at
ClinicalTrials.gov (NCT01181271).
Participants were enrolled between October 2010 and June 2013. Pa-
tients were 18 years of age and had an Eastern Cooperative Oncology
Group performance status score of 0 to 2, a left ventricular ejection fraction
 45%, adequate pulmonary function tests (forced expiratory volume in 1
second, forced vital capacity, and diffusing capacity of the lungs for carbon
monoxide all 50% of predicted), total serum bilirubin < 2.0 mg/dL, trans-
aminases < 3 times the upper limit of normal, and serum creatinine < 2.0
mg/dL. Disease eligibility was as follows: (1) diffuse large B cell lymphoma
(DLBCL) or transformed low-grade NHL with residual disease after at least 6
cycles of anthracycline-based chemotherapy, progressive disease after at
least 2 cycles of anthracycline-based chemotherapy, or disease relapse
within 12 months after completion of anthracycline-based chemotherapy;
(2) indolent B cell NHL refractory to most recent therapy or relapsed within
12 months after most recent therapy; (3) any peripheral T cell NHL
(excluding cutaneous T cell lymphoma); (4) mantle cell lymphoma; (5)
“double-expressing” DLBCL characterized by concurrent over-expression of
BCL-2 and MYC proteins; and (6) HL refractory to at least 1 standard salvage
chemotherapy regimen.
The trial did not require that a suitable donor be identiﬁed before
enrollment. To assess disease response before AutoSCTand AlloSCT, positron
emission tomography (PET) was preferred, but standard computed tomog-
raphy images were allowed.
AutoSCT
Autologous hematopoietic stem cell mobilization was carried out per
physician discretion using methods such as chemotherapy with granulocyte
colony-stimulating factor (G-CSF), G-CSF alone, and G-CSF with plerixafor.
Leukapheresis was performed per institutional standard, and a minimum of
2  106 CD34þ cells/kg was required to enroll. Myeloablative conditioning
consisted of busulfan (.8mg/kg i.v. every 6 hours 14 doses for a total of 11.2
mg/kg i.v. given on days 8, 7, 6, and 5), cyclophosphamide (60 mg/kg/
day i.v. on days3 and2), and etoposide (30mg/kg i.v. on day4) (BuCyE).
Busulfan pharmacokinetic levels were not measured, and no dose adjust-
ments were made. All patients were hospitalized from admission until
neutrophil engraftment. G-CSF was started on day þ1 and given daily until
engraftment. Infectious prophylaxis was per institutional norm but included
agents against bacteria when neutropenic and varicella-zoster and Pneu-
mocystis jirovecii upon discharge.
RIC AlloSCT
Once patients recovered, theywere allowed to proceed to RIC AlloSCT 40
to 180 days after AutoSCT. All eligibility tests and disease restaging were
repeated, and participants with progressive disease were taken off trial. RIC
consisted of busulfan 3.2 mg/kg i.v. (.8 mg/kg i.v. daily  4 days) and
ﬂudarabine 120 mg/m2 (30 mg/m2 i.v. daily  4 days). Donors were 8/8-
matched (HLA-A, -B, -C, and -DRB1 by allele level typing) related or
unrelated donors. Peripheral blood stem cell products were mobilized with
G-CSF and collected by leukapheresis.
Graft-versus-host disease (GVHD) prophylaxis was composed of tacro-
limus, sirolimus, and low-dose methotrexate (5 mg/m2 i.v. given on
days þ1, þ3, and þ6). Tacrolimus and sirolimus were both started orally on
day 3, and therapeutic trough levels were recommended until dayþ90; in
the absence of active GVHD, they were tapered off by day þ180. Prophylaxis
against varicella-zoster virus and P. jiroveciiwas continued through at least 1
year after AlloSCT. Cytomegalovirus was monitored routinely after AlloSCT,
and signiﬁcant reactivation was treated pre-emptively.Statistical Considerations
The primary objective of this study was to assess engraftment after this
tandem AutoSCTeRIC AlloSCT approach. The tandem transplant approach
was considered feasible if at least 65% of the eligible patients who completed
AutoSCTwere able to proceed to the allogeneic transplant. It was envisioned
that 40 patients would enter the study and undergo AutoSCT. Of these 40,
we predicted that 15 would not be eligible to proceed to AlloSCT for various
reasons that would not apply toward evaluation of feasibility, including
patient choice, lack of a suitable donor, or disease progression. Of these 25
patients, if at least 14 patients proceeded to undergo RIC AlloSCT, this tan-
dem transplant design would be considered feasible.
The primary endpoint of the study was donor stem cell engraftment as
measured by peripheral blood all cell chimerism before measurement at
day þ100 after RIC AlloSCT. Secondary endpoints included incidence of
nonrelapse mortality (NRM) at 100 days and 1-year after AlloSCT, 2-year
progression-free survival (PFS), 2-year overall survival (OS), cumulative
incidence of grades II to IV and III to IV acute GVHD by day þ200, and cu-
mulative incidence of chronic GVHD requiring systemic immunosuppres-
sion. An early stopping rulewaswritten in the case of excessiveNRMwhere if
3 or more cases of NRMwere observed in the ﬁrst 100 days after RIC AlloSCT
in the ﬁrst 10 patients, the study would be terminated for safety reasons.RESULTS
AutoSCT
Forty-two 42 patients were enrolled and underwent
AutoSCT. Twenty-nine patients proceeded to RIC AlloSCT.
Clinical and transplant characteristics are presented in
Table 1. Median patient age was 56.5 (range, 22 to 69), and
62% of patients were men. Forty-one patients had various
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engrafted both neutrophils and platelets after BuCyE
AutoSCT, and no NRM was observed after AutoSCT. Thirteen
patients did not proceed to RIC AlloSCT because of disease
progression in 6, patient choice in 4, no available suitable
donor in 2, and therapy-related acute myeloid leukemia in 1.
Three of these patients eventually underwent RIC AlloSCT
after other treatments.
RIC AlloSCT
Twenty-nine patients underwent the full tandem
AutoSCTeRIC AlloSCT, and their clinical characteristics are
shown in Table 1. Sixteen patients received stem cell prod-
ucts frommatched related donors, whereas 13 patients were
recipients of matched unrelated donor grafts. Before
AutoSCT, 14 patients were in complete remission (CR),
whereas 15 were in partial remission (PR). Before RIC
AlloSCT, 23 patients had achieved CR and 6 were in PR. PET
imaging was performed for response assessment in 28 of 29
patients.
The median time from AutoSCT to RIC AlloSCT was 96
days (range, 48 to 169). All patients engrafted successfully,
with a day þ100 median peripheral blood all-cell donor
chimerism of 95% (range, 83% to 99%). Day þ100 median
peripheral blood T cell chimerism was 80% (range, 38% to
100%). Of the 17 patients who experienced a hematological
nadir, time to neutrophil engraftment occurred at a median
of 12 days (range, 1 to 18) and time to platelet engraftment
occurred at a median of 13 days (range, 9 to 41).
GVHD and NRM
As shown in Table 2, the cumulative incidence by day 180
after AlloSCT of grades II to IV acute GVHD was 13.8% (90%
conﬁdence interval [CI], 5.3% to 26.3%). The cumulative 1-
year incidence of chronic GVHD requiring systemic immu-
nosuppressionwas 37.9% (90% CI, 23.1% to 52.7%). Therewere
no deaths from nonrelapse causes before day 100. The 1-year
and 2-year cumulative incidences of NRM were 6.9% (90% CI,
1.7% to 17.5%) and 11.1% (3.5% to 23.6%), respectively. Causes
of death included sepsis (n ¼ 1), bronchiolitis obliterans
(n ¼ 1), and respiratory failure due to P. jiroveci pneumonia
(n ¼ 1).
Relapse
The 1-year and 2-year cumulative incidences of disease
relapse were 13.8% (90% CI, 5.3% to 26.3%) and 17.2% (90% CI,
7.5% to 30.4%), respectively, resulting in 5 total cases of
relapse in patients who underwent tandem transplantation.
All 5 patients had DLBCL by histology, 3 of whom were
transformed from underlying indolent NHL. All were in a
partial remission before AutoSCT by PET imaging, and 4 of
them did not achieve CR after AutoSCT and were in PR by PETTable 2
Outcomes after Tandem ASCT-RIC AlloSCT (n ¼ 29)
Outcome %
Grades 2-4 acute GVHD* 13.8 (90% CI, 5.3-26.3)
Chronic GVHD requiring systemic
immunosuppressiony
37.9 (90% CI, 23.1-52.7)
2-year incidence of NRM 11.1 (90% CI, 3.5-23.6)
2-year incidence of relapse 17.2 (90% CI, 7.5-30.4)
2-year PFS 72 (90% CI, 55-83)
2-year OS 89 (90% CI, 74-86)
* Cumulative incidence by day þ180.
y Cumulative incidence by 1 year.imaging before RIC AlloSCT. Four of these patients received
donor leukocyte infusions as part of their salvage therapies
after disease relapse and were able to achieve CR. No patient
who underwent tandem transplantation has died from cau-
ses related to their underlying disease.
Survival
Median follow-up for all surviving patients was 30.0
months (range,17.1 to 51.5). The estimated 2-year PFS rate for
all patients was 64% (90% CI, 50% to 75%) and the estimated
2-year OS rate 83% (90% CI, 70% to 90%) (Figure 1). Median
follow-up for survivors after RIC AlloS CT was 29.5 months
(range, 17.1 to 48.0). The estimated 2-year PFS rate for pa-
tients undergoing the tandem procedure was 72% (90% CI,
55% to 83%) and the estimated 2-year OS rate 89% (90% CI,
74% to 96%) (Table 2, Figure 2). The estimated 2-year PFS rate
for patients undergoing AutoSCTalone (n¼ 13) was 46% (90%
CI, 23% to 66%) and the 2-year OS rate 69% (90% CI, 43% to
85%); however, several of these relapses occurred before
planned RIC AlloSCT could be performed.
Double-Expressing DLBCL
Of the 9 patients with double-expressing DLBCL, 5
possessed concurrent translocations of both MYC and BCL-2,
3 had extra copies of MYC and a BCL-2 translocation, and 1
patient had over-expression of both MYC and BCL-2 as
assessed by immunohistochemistry. Seven of these patients
underwent the tandem procedure, whereas 2 patients
received AutoSCT alone. None of these patients experienced
disease relapse and 1 patient died from nonrelapse causes.
DISCUSSION
Although many patients with relapsed HL or NHL achieve
a durable remission with high-dose chemotherapy and
AutoSCT, disease relapse remains a frequent cause of death in
this patient population. No consolidative or maintenance
therapies administered to patients in remission after
AutoSCT have shown an OS beneﬁt to date. We conducted a
phase II study of tandem AutoSCTeRIC AlloSCT in patients
with various lymphoma histologies that we considered at
high risk for recurrence after AutoSCT. Our results validate
that this is a feasible approach with acceptable morbidityFigure 1. Progression-free and overall survival in all patients (n ¼ 42).
Figure 2. Progression-free and overall survival in patients undergoing tandem
transplantation (n ¼ 29).
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trated by a 2-year NRM rate of 11%. With a median follow-up
of 30 months, our estimated 2-year PFS and OS rates for
patients who underwent AutoSCTeRIC AlloSCTwere 72% and
89%, respectively.
The logic of tandem autologouseallogeneic trans-
plantation is rooted in the ability to deliver both the cyto-
toxicity of high-dose chemotherapy and the immunologically
driven graft-versus-malignancy effect of allogeneic trans-
plantation. Historically, this was provided by conventional
myeloablative AlloSCT, yet long-term rates of NRM with
myeloablative AlloSCT in patients with lymphoma are unac-
ceptablyhigh [10]. Hence, the tandemapproach canhopefullyTable 3
Published Experience with Tandem AutoSCTeRIC AlloSCT for Lymphoma
Study n Diagnosis ASCT
Carella et al. 2000 15 NHL (33%)
HL (67%)
BEAM
Gutman et al. 2005 23/32 NHL (84%)
HL (16%)
BuCy (22%)
BEAM (78%)
Sorror et al. 2009 37 NHL (67%)
HL (21%)
CLL (12%)
BEAM (48%)
CyTBI (52%)
Cohen et al. 2012 27 Follicular NHL
(5 transformed)
BEAC (52%)
BEAM (48%)
Crocchiolo et al. 2013 34 NHL BEAM (53%)
Mel (47%)
Satwani et al. 2014 23/30 (Peds) HL (53%)
NHL (47%)
CBV
Wudhikarn et al. 2014 12/34 NHL e
Chen et al. 2015 29/42 NHL (98%)
HL (2%)
BuCyE
RIC AlloSCT indicates reduced intensity conditioning-allogeneic stem cell transpla
phamide; TBI, total body irradiation; MRD, matched related donor; URD, unrelated
cyclophosphamide/total body irradiation; BEAC, BCNU, etoposide, ara-C and cyclop
3.2 mg/kg i.v. (.8 mg/kg i.v. daily  4 days) and ﬂudarabine 120 mg/m2 (30 mg/mprovide similar therapeutic beneﬁts yet minimize treatment-
associated morbidity and mortality. This strategy has been
widely explored inmultiplemyelomawithmixed results [12-
16]. What is clear from the myeloma experience is that any
beneﬁt from a tandem transplant approach will be observed
in a high-risk subset of patients, and long-term follow-up is
needed to demonstrate such a beneﬁt.
Several series have explored tandem autologouse
allogeneic transplantation for patients with lymphoma, and
these are summarized in Table 3. Carella et al. [17] ﬁrst
described 15 patients (10 HL, 5 NHL) treated with BCNU,
etoposide, cytarabine, and melphalan AutoSCT followed by
ﬂudarabine/cyclophosphamide RIC AlloSCT from matched
related donors. Eleven patients achieved CR, including 9
patients who were in PR after AutoSCT, and 2 patients died
from nonrelapse related causes. Seven patients achieved
mixed chimerism and required early immunosuppression
withdrawal and/or donor leukocyte infusion to achieve full
donor chimerism. Gutman et al. [18] treated 32 patients, 23
of whom underwent the full tandem procedure. Although
the early day 100 transplant-related mortality was only 9%,
overall transplant-related mortality was quite high at 43%
due to GVHD and infectious complications. This resulted in a
median PFS and OS of only 157 and 385 days, respectively.
Series published more recently have showed much more
promising results. Cohen et al. [19] described 27 patients
with advanced follicular NHL (5 with transformed disease)
who underwent tandem autologouseallogeneic transplant.
With a median follow-up of 39months, 3-year estimated PFS
and OS rates were both 96%. The NRM rate was only 4%, with
1 patient dying from GVHD-related complications. Impres-
sively, no patients experienced disease progression from a
cohort with a median of 3 lines of prior therapy, 14 patients
in PR, and 5 patients with refractory disease at the time of
enrollment. Most recently, Crocchiolo et al. reported out-
comes in 34 patients with advanced NHL. With a medianRIC AlloSCT NRM PFS OS F/u
Flu/Cy 2 pts 5 pts 10 pts 337 d
TBI or Flu/TBI
MRD (65%)
URD (22%)
UCB (13%)
43% 157 days
(median)
385 days
(median)
e
TBI or Flu/TBI
MRD (76%)
URD (24%)
16% 47% (2-yr) 55% (2-yr) 39 mo
Flu/Cy
MRD (100%)
4% 96% (3-yr) 96% (3-yr) 39 mo
Bu/Flu/ATG or
Flu/Cy  thiotepa
MRD (85%)
URD (15%)
6% 68% (5-yr) 77% (5-yr) 46 mo
Bu/Flu
MRD (26%)
URD (35%)
UCB (39%)
12% 64% (10-yr) e 60 mo
e e 37.7 mo
(median)
Median
not reached
10 mo
BuFlu
MRD (55%)
URD (45%)
11.1% 72% (2-yr) 89% (2-yr) 29.5 mo
ntation; F/u, follow-up; Cy, cyclosphosphamide; BuCy, busulfan/cyclophos-
donor; UCB, umbilical cord blood; CLL, chronic lymphocytic leukemia; CyTBI,
hosphamide; Mel, melphalan; ATG, anti-thymocyte globulin; BuFlu, busulfan
2 i.v. daily  4 days).
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tality rate was only 6%, with 5-year PFS and OS rates of 68%
and 77%, respectively [20]. Three other tandem transplant
lymphoma series have also been presented in preliminary
abstract form and are shown in Table 3.
Our study adds to the growing literature of using a tan-
dem transplant strategy for patients with high-risk lym-
phoma in the modern era and helps to build the rationale to
study the efﬁcacy of this approach in a deﬁned homogeneous
population. In total, from the 8 series shown in Table 3, 200
patients have now been treated with tandem transplantation
for lymphoma. The most recent series, including ours, have
found a progressive decrease in overall NRM and an increase
in rates of PFS and OS. Indeed, unexpected toxicity and failure
of engraftment are no longer concerns with such an
approach. These recent improvements likely reﬂect a com-
bination of several factors, including better patient selection,
more accurate HLA matching, improvements in supportive
care, and advances in salvage chemotherapy. Not surpris-
ingly, in our series, those who were able to achieve a CR after
AutoSCT and before RIC AlloSCT had the best outcomes. In
addition, it is notable that 4 of the 5 patients who relapsed
after AlloSCT received donor leukocyte infusions as part of
salvage therapy to achieve remission again, an option that
would not have been available if AlloSCT had not been per-
formed. No patients who underwent tandem transplantation
have died from disease progression thus far.
There are several limitations of our study. First, this was a
single-arm, phase II trial and, hence, there was no control
arm to allow comparison of efﬁcacy. Second, as stated above,
the clinical heterogeneity of diagnoses included makes any
efﬁcacy endpoint difﬁcult to interpret even compared with
historical control subjects. Nevertheless, the relatively low
rate of NRM does justify investigating this approach further
for patients whose disease response can be maintained long
enough to proceed through both transplant procedures.
With the advances in alternative donor transplantation over
the last decade [21], it is also tempting to include patients
who could receive grafts from haploidentical donors or
umbilical cord blood, thus overcoming a major obstacle.
Nevertheless, given that the leading reason for not being able
to undergo AlloSCTon trial was disease progression, it is clear
that novel approaches beyond tandem transplantation are
needed for a subset of patients whose disease does not
optimally respond to AutoSCT.
To truly prove a place for this approach, a prospective
study in a deﬁned homogeneous population to test efﬁcacy is
needed. Potentially, the appropriate patients are those with
relapsed DLBCL in whom the standard of care has remained
AutoSCT for the past 2 decades [22], yet durable remission is
achieved in only approximately 40% to 50%. Identifying a
high-risk subset of such patients has proven challenging.
Although the Collaborative Trial in Relapsed Aggressive
Lymphoma (CORAL) study highlighted several clinical risk
factors that predicted a worse prognosis at the time of
relapse [23], it appears that if a CR can be achieved, the
prognosis with AutoSCT remains similar to other patients.
This has been validated by several single-center series
[24-26] as well as a recent study from the Center for Inter-
national Blood and Marrow Transplant Research registry,
which illustrated that disease response to salvage chemo-
therapy was the most important clinical factor predictive of
prognosis for patients undergoing AutoSCT [27]. Including
functional imaging into risk stratiﬁcation may potentially be
how we can deﬁne a high-risk population as illustrated byour recent series [28], and 1 idea would be to conduct a
phase II tandem transplant study in patients with relapsed
DLBCL who remain positive by PET imaging after 2 cycles of
conventional salvage chemotherapy.
Even with the promising results observed in our series
and others, it is important to note that trials of newer ther-
apies such as immunological checkpoint inhibitors [29] or
chimeric antigen receptor T cells [30] may obviate the
approach of tandem transplantation. Certainly, these thera-
pies appear to be safer in terms of risk for infection and an
absence of GVHD; however, long-term follow-up is needed
to substantiate efﬁcacy, especially if used as maintenance
after AutoSCT. In addition, future comparisons will need to
analyze secondary endpoints such as quality of life and cost
to appropriately determine which therapies are optimal to
administer after AutoSCT in efforts to reduce disease relapse.
In conclusion, high-dose chemotherapy with AutoSCT
followed by RIC AlloSCT is a safe and effective therapeutic
approach for patients with high-risk lymphoma. It is unclear
if certain histological, clinical, or biological subtypes beneﬁt
from tandem transplantation compared with AutoSCT or RIC
AlloSCT alone. Prospective clinical trials in homogeneous
patient populations are warranted to deﬁne the place of
tandem transplantation in the treatment of patients with
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